Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Advanced Refractory Urothelial Cancer
NCT02122172Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Sep 2017
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in urothelial carcinoma (UC), sponsored by University of Chicago. Started Sep 2017; status: terminated.
02
Drugs
afatinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02122172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02122172.